Skip to search formSkip to main contentSkip to account menu
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
TLDR
A systematic review of studies reporting LEDs yielded a standardized LED for each drug, providing a useful tool to express dose intensity of different antiparkinsonian drug regimens on a single scale.
View on Wiley
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
TLDR
Early Parkinson's disease can be managed successfully for up to five years with a reduced risk of dyskinesia by initiating treatment with ropinirole alone and supplementing it with levodopa if necessary.
View on PubMed
Idiopathic intracranial hypertension
View on Elsevier
Physiotherapy versus placebo or no intervention in Parkinson's disease.
TLDR
Benefit for physiotherapy was found in most outcomes over the short-term, but was only significant for velocity, two- or six-minute walk test, step length, Timed Up & Go, Functional Reach Test, Berg Balance Scale and clinician-rated UPDRS.
View on PubMed
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
View on Elsevier
Physiotherapy intervention in Parkinson’s disease: systematic review and meta-analysis
TLDR
Systematic review and meta-analysis of randomised controlled trials found no evidence that the treatment effect differed across the interventions for any outcomes assessed, apart from motor subscores on the unified Parkinson’s disease rating scale.
View on Publisher
Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's disease
TLDR
This study screened 136 EOPD probands from a high‐ascertainment regional and community‐based prevalence study for pathogenic mutations in PARK2 (parkin), PINK1, PARK7 (DJ‐1), and exon 41 of LRRK2 and shows an increased likelihood of mutations in patients with lower AAO, family history, or parental consanguinity.
View on Wiley
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole
TLDR
The rotigotine transdermal patch represents an effective and safe option for the treatment of patients with early Parkinson's disease and the most common adverse events were application‐site reactions, nausea, and somnolence.
View on Wiley
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
TLDR
It is suggested that multiple genetic hits may act in combination to degrade lysosomal function, enhancing Parkinson's disease susceptibility.
View on Wolters Kluwer
Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
View on Elsevier
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License